Cellectar Announces Oral Presentation at the 61 st Annual American Society of Hematology Conference

Oral Presentation at the 61st Annual American Society of Hematology Conference

N.J., December 2, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical

company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced an oral

presentation at the 61st Annual American Society of Hematology (ASH) meeting being held December 7-10, 2019 in Orlando,

Presentation details:

poster can be accessed on the Posters and Publications section of the Cellectar website on the day of the poster presentation.

Cellectar Biosciences

is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing

proprietary drugs independently and through research and development (R&D) collaborations. The company's core objective

is to leverage its proprietary Phospholipid Drug ConjugateTM (PDC) delivery platform to develop PDCs that specifically

target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's

PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and

it plans to develop PDCs independently and through research and development collaborations.

lead PDC therapeutic, CLR 131, is currently in three clinical studies - a Phase 2 study, and two Phase 1 studies. The Phase

2 clinical study (CLOVER-1) is in relapsed/refractory (R/R) B-cell malignancies, including multiple myeloma (MM), chronic lymphocytic

leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma

(MCL), and diffuse large B-cell lymphoma (DLBCL). The company is also conducting a Phase 1 dose escalation study in patients with

R/R multiple myeloma (MM) and a Phase 1 study in pediatric solid tumors and lymphoma.

product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900) and several partnered PDC assets.

For more information,

please visit www.cellectar.com or join the conversation by liking and following us on our social media channels: Twitter,

LinkedIn, and Facebook.

Forward-Looking Statement Disclaimer

contains forward-looking statements. You can identify these statements by our use of words such as "may", "expect",

"believe", "anticipate", "intend", "could", "estimate", "continue",

"plans", or their negatives or cognates. These statements are only estimates and predictions and are subject to known

and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements

made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development

involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related

to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of CLR 131, the

ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development

thereof, the completion of clinical trials, the FDA review process and other government regulation, the volatile market for priority

review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition

from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties

related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form

10-K for the year ended December 31, 2018 and Form 10-Q for the quarters ended March 31, 2019, June 30, 2019 and September 30,

2019. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking